Suit filed in India to close Ranbaxy plants, probe company

06/10/2013 | BioSpectrum Asia

Following a $500 million settlement with the US FDA over selling adulterated drugs, the generic-drug firm Ranbaxy Laboratories is facing a public-interest lawsuit in India to shutter the two Indian manufacturing plants involved in the FDA settlement and launch a companywide investigation. The lawsuit alleges "outright fraud, in which the company knowingly sold substandard drugs around the world." Ranbaxy disputed the allegations, stating that all of its products are safe and effective.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA